



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/784,507	02/23/2004	Ken Rosenblum	1326.001US5	1482
21186	7590	01/06/2006	EXAMINER	
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH 1600 TCF TOWER 121 SOUTH EIGHT STREET MINNEAPOLIS, MN 55402			MAI, THIEN T	
			ART UNIT	PAPER NUMBER
			2876	

DATE MAILED: 01/06/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/784,507	Applicant(s) ROSENBLUM, KEN	
	Examiner Thien T. Mai	Art Unit 2876	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 November 2005.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 23 February 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Acknowledgement

1. Acknowledgement is hereby made of the terminal disclaimers received on 11/14/2005. Claims 1-16 remain under prosecution presented herein.
2. Acknowledgement is hereby made of the Amendment received on 11/14/2005, in which the Abstract was amended to overcome Examiner's objection in previous Office Action. Therefore, previous objection is withdrawn.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

4. Claim(s) 1-3 and 6-10 and 12-16 is/are rejected under 35 U.S.C. 102(e) as being anticipated by Schoonen (US 6,230,927)

Regarding claim(s) 1, Schoonen discloses a method comprising:

giving the unique one-time drug identification code as the authorization code for multiple drugs in a prescription by a doctor stored on customer's chip card or transmitted to the server computer at a pharmacy location where the automatic dispenser is located, wherein said authorization code can be used to obtain one time for a single prescription for drugs that are prepackaged in cartridge for the customer/patient to pickup when the patient/customer enters said authorization code into the dispenser without intervention of a pharmacist; wherein the doctor can be interpreted as being a healthcare provider

Art Unit: 2876

at a health care facilities such as hospital or a physician's office (see abstract, col. 1 lines 20-65, col. 7 lines 1-5).

Regarding claim(s) 2, Schoonen discloses the patient receives the prescribed therapeutic agent from the dispensing apparatus without the intervention of a pharmacist. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 3, Schoonen discloses unique authorization code is given to the patient by a health care provider at a health care facility. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 6, Schoonen discloses the unique authorization code is unique to the prescription and only associated with a single prescription. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 7, Schoonen discloses a method comprising:
providing a dispenser containing an inventory of therapeutic products; transmitting a proposed prescription for a patient to a server; authorizing dispensing of at least a portion of the proposed prescription out of the inventory in the dispenser if the prescription includes at least one therapeutic product available in the inventory of the dispenser; providing to the patient an authorization code unique to the authorized prescription, the authorization code not capable of being reused for other prescriptions; the patient inputting the authorization code into the dispenser; and the dispenser delivering the available therapeutic product to the patient in response to the patient inputting the authorization code. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 8, Schoonen discloses the authorization step is done without the intervention of a pharmacist. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 9, Schoonen discloses the patient receives the therapeutic agent from the dispenser without the intervention of a pharmacist. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Art Unit: 2876

Regarding claim(s) 10, Schoonen discloses the authorization code is given to the patient by a health care provider at a health care facility.

Regarding claim(s) 12, Schoonen discloses a method comprising giving the unique one-time drug identification code as the authorization code for multiple drugs in a prescription by a doctor stored on customer's chip card or transmitted to the server computer at a pharmacy location where the automatic dispenser is located, wherein said authorization code can be used to obtain one time for a single prescription for drugs that are prepackaged in cartridge for the customer/patient to pickup when the patient/customer enters said authorization code into the dispenser without intervention of a pharmacist; wherein the doctor can be interpreted as being a healthcare provider at a health care facilities such as hospital or a physician's office (see abstract, col. 1 lines 20-65, col. 7 lines 1-5)

wherein the dispenser is authorized to dispense the whole prescription out of the dispenser's inventory if the prescription drug is available for dispense, otherwise the patient will receive nothing; and wherein the authorizing is done by the doctor who saves the prescription in the patient's card, therefore intervention by pharmacist is unnecessary (see abstract, col. 1 lines 20-65, col. 7 lines 1-5).

Regarding claim(s) 13, Schoonen discloses the data includes a one-time-use authorization code associated with only the adjudicated prescription. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 14, Schoonen discloses the data includes a unique authorization code that is not capable of being reused. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 15, Schoonen discloses the therapeutic product is delivered to the patient without the intervention of a pharmacist. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Regarding claim(s) 16, Schoonen discloses adjudicating the proposed prescription into an adjudicated prescription is done without the intervention of a pharmacist. See abstract, col. 1 lines 20-65, col. 7 lines 1-5.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claim(s) 4-5 and 11 is/are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoomen (US 6,230,927) in view of Lion (US 4,732,411). The teachings of Schoonen have been discussed above.

Regarding claim(s) 4, Schoonen discloses the authorization code is given to the patient by a doctor (see abstract, col. 1 lines 20-37, col. 7 lines 1-5).

Schoonen does not disclose or fairly suggest the authorization is given to the patient by a pharmacist.

Lion discloses an automatic prescription dispenser for dispensing prescription drug without intervention of a local operator, wherein the dispenser receives a pre-assigned identification as the authorization code through a mail order pharmacy, which inherently implies the pharmacy having at least a technician/pharmacist performing the function of assigning the authorization code to the patient; wherein the dispenser also receives payment in the form of debit or credit card (col. 3 lines 27-40, col. 6 lines 1-10, col. 6 lines 35-50).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate Lion's teachings to Schoomen by assigning a unique and single use prescription identification by a pharmacy technician or pharmacist.

One of ordinary skill in the art should be motivated to employ the pharmacy-assigned prescription identification as taught by Lion so that traffic at the pharmacy can be alleviated and customer

Art Unit: 2876

wait time for the prescription fill status can be minimized by entering the authorization code in the dispenser for the prescription rather than continuously requesting the status from the pharmacy staff.

Regarding claim(s) 5, Lion discloses the dispenser also receives payment in the form of debit or credit card (col. 3 lines 27-40, col. 6 lines 1-10, col. 6 lines 35-50).

Regarding claim(s) 11, Lion discloses the authorization code is given to the patient by a pharmacist or pharmacy technician at a pharmacy (col. 3 lines 27-40, col. 6 lines 1-10, col. 6 lines 35-50).

Art Unit: 2876

Conclusion


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thien T. Mai whose telephone number is 571-272-8283. The examiner can normally be reached on Monday through Friday, 8:00 - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Lee can be reached on 571-272-2398. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Thien T Mai
Examiner
Art Unit 2876

TM



MICHAEL G. LEE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 2800